Charles River Laboratories International Inc CRL
News
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories’ Directors and Officers for Breach of Fiduciary Duties
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories’ Directors and Officers for Breach of Fiduciary Duties
Agilon Health, Inc, B. Riley Financial, Charles River Laboratories, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Charles River Laboratories Announces Second-Quarter 2024 Results
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Agilon Health, Inc, B. Riley Financial, Charles River Laboratories, and Vertex Energy Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories’ Directors and Officers for Breach of Fiduciary Duties
Charles River to Perform Plasmid Manufacturing for AAVantgarde